Lorcaserin
Detailed Description
Product Name:Lorcaserin
Product Name Lorcaserin
Synonym Belviq, Apd 356, (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CAS 616202-92-7
MF C11H14ClN
MW 195.692
Assay 99.5%
Quality Standards USP
Appearance White to almost white crystalline powder
Package 1kg/Foil bag
Place of Origin China
Brand Name SMQ
Certification ISO9001, ISO14000, KOSHER
MOQ 10g
Packaging Details 1kg/bag,100g/bag, 10g/bag
Delivery Time 1-3 days
Payment Terms T/T, Western union, Money gram
Supply Ability 1000KGS/week
1.OverView:
Lorcaserin (APD-356, trade name upon approval Belviq, expected trade name during development, Lorqess is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. On 22 December 2009 a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted to recommend against approval of the drug based on concerns over both safety and efficacy.
2.Description:
Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety.
- Lorcaserin
View Contact Detail